Please login to the form below
EGFR inhibitor
This page shows the latest EGFR inhibitor news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca shares positive phase 3 results for Tagrisso combination in lung cancer
NSCLC) to receive the Tagrisso/chemotherapy combination or the EGFR-tyrosine kinase inhibitor alone. ... Approximately 10% to 15% of NSCLC patients in the US and Europe have EGFRm NSCLC, with this patient population particularly sensitive to treatment
Latest news
-
Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
lazertinib for patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations. ... The phase 1b/2 CHRYSALIS-2 study is an ongoing clinical trial evaluating Rybrevant in combination with lazertinib, a
-
New data advances AstraZeneca’s “revolution in oncology”
kinase inhibitor, in patients with advanced EGFR-mutated (EGFRm) NSCLC with MET alterations whose disease progressed on first-line Tagrisso. ... OReO, the first phase 3 trial to evaluate retreatment with a PARP inhibitor in resistant disease.
-
AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU
AstraZeneca’s (AZ) third-generation EGFR tyrosine kinase inhibitor (TKI) Tagrisso has been approved to treat early-stage EGFR mutated non-small cell lung cancer (NSCLC) in the EU. ... NSCLC. Janssen assessed the investigational drug in combination
-
AZ forecasts growth in 2021 after revenues surge in Q4
In 2020, oncology growth was up by 23% to $11.45bn, with the top-selling product being AZ’s EGFR-tyrosine kinase inhibitor Tagrisso (osimertinib). ... AZ also reported significant sales growth for checkpoint inhibitor Imfinzi (durvalumab) and PARP
-
Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer
Braftovi (encorafenib) combined with has been recommended Merck KGaA’s EGFR-targeting antibody Erbitux (cetuximab) has been recommended as a second-line treatment for BRAF-positive metastatic colorectal cancer (mCRC). ... The trial also demonstrated
More from news
Approximately 1 fully matching, plus 78 partially matching documents found.
Latest Intelligence
-
Interview: AstraZeneca's Susan Galbraith
EGFR-TK) inhibitor, which has so far been approved in non-small cell lung cancer, albeit after a much-delayed, stop-start regulatory journey. ... If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Streaming Well
Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
